Herbeuval Jean-Philippe | Immunology Cellular Interactions | Best Innovator Award

Posted on by sciencefather

Dr. Herbeuval Jean-Philippe | Immunology Cellular Interactions | Best Innovator Award

Dr. Herbeuval Jean-Philippe | CNRS | France

Jean-Philippe Herbeuval is a French immunologist and CNRS Director of Research, renowned for pioneering contributions to translational immunology and biomedical innovation. A PhD holder in immuno-oncology, he completed a prestigious Fogarty Fellowship at the NIH, USA, where he earned the Norman P. Salzman Award. He founded and leads the CBMIT team at Université Paris Cité, integrating immunology, virology, and chemistry for therapeutic discovery. Herbeuval has launched two biotech companies: Ermium Therapeutics, based on anti-interferon therapies, and Elyris Pharma, centered on PDK1 as a novel anti-inflammatory target. With 9 patents (3 licensed), €8.8M in research funding, and >70 publications (h-index 28), his innovations span diagnostics to therapeutics. He also contributes to policy and innovation strategy through national and international committees. Recognized for his vision, leadership, and mentorship, Herbeuval exemplifies the intersection of academic research and impactful biotechnology entrepreneurship.

Publication Profile:

Google Scholar

✅ Strengths for the Award:

  1. Exceptional Innovation in Immunology & Therapeutics

    • Discovered key therapeutic targets such as CXCR4 and PDK1.

    • Founded Ermium Therapeutics (2019) and Elyris Pharma (2024), securing over €12M in funding.

    • Holds 9 patents, with 3 already licensed — a key indicator of translational success.

  2. Proven Scientific Leadership

    • Director of Research (CNRS), Head of CBMIT at Université Paris Cité.

    • Established and led multiple interdisciplinary research teams and platforms (Cyto2BM, CBMIT).

    • Supervised 10 PhD students, 7 postdocs, and over 18 master’s students, many of whom reached elite positions.

  3. High-Impact Research Output

    • 70+ publications, including high-citation studies on interferon signaling in HIV.

    • Over 3,500 citations, h-index: 28 — showing strong impact and visibility.

  4. Strong National and International Recognition

    • Winner of the prestigious i-Lab National Innovation Prize (France, 2019).

    • Invited speaker at over 24 international conferences; reviewer for Nature Medicine and PNAS.

    • Advisor for funding agencies across the US (NIH), UK (MRC), China, and Brazil.

  5. Valuable Public and Government Engagement

    • CNRS Innovation Ambassador (2024) and expert for multiple national programs (ANRS, Campus France).

    • Actively engages in public science communication (TV, radio, press).

🔧 Areas for Improvement:

  1. Scaling Global Industry Impact

    • While Ermium and Elyris are high-potential, further proof of market adoption and therapeutic success will solidify his innovation leadership globally.

  2. Broader Patent Commercialization

    • More patents could potentially be moved from licensing to full-scale clinical trials or product development phases.

  3. Diversity of Therapeutic Areas

    • While the focus on interferon biology and immunomodulation is powerful, broader expansion into other disease domains (e.g., neuroinflammation, metabolic syndromes) could enhance reach.

🎓 Education:

Jean-Philippe Herbeuval earned his PhD in immuno-oncology in 2001 from Université Jean Monnet, Saint-Étienne, working under the INSERM network. He then pursued a highly competitive five-year Fogarty Postdoctoral Fellowship at the National Institutes of Health (NIH), USA, under Dr. Gene Shearer, focusing on the antiviral response to HIV. During this time, he earned multiple prestigious awards including the Norman P. Salzman Award and an NIH Young Scientist Cash Award. Upon returning to France, he secured a CNRS Junior PI position in 2006 and received his Habilitation to Direct Research (HDR) in 2008 from Université Paris Descartes. His rapid career progression continued with his appointment as Director of Research (2nd class) in 2013 and promotion to 1st class in 2019 at CNRS UMR8601. His educational path reflects an exceptional blend of scientific rigor, international exposure, and leadership in innovation.

💼 Experience:

Jean-Philippe Herbeuval brings over two decades of distinguished experience at the interface of academic research and biotech innovation. Starting with his postdoctoral fellowship at NIH (2001–2006), he led groundbreaking studies on interferon responses in HIV. Since 2006, he has served within CNRS, creating and leading the CBMIT interdisciplinary team. He established the Cyto2BM core facility and spearheaded multiple translational projects. As scientific founder of Ermium Therapeutics (2019) and Elyris Pharma (2024, in progress), he has successfully attracted venture capital and secured technology transfer agreements. His strategic involvement extends to national innovation committees (ANRS, CNRS, Campus France) and advisory roles. He has trained over 35 researchers and supervised major national/international grants. Notably, he combines deep scientific insight with an entrepreneurial mindset, as shown by his participation in Deeptech Founders and RISE programs. His experience spans leadership, translational science, investment negotiations, and scientific mentoring.

🔬 Research Focus:

Jean-Philippe Herbeuval’s research is centered on translational immunology, particularly type I interferons, autoinflammatory pathways, and host-pathogen interactions. His work explores immune dysregulation in infectious diseases such as HIV, SARS-CoV-2, dengue, and influenza, with a special focus on the immune-modulatory roles of dendritic cells and apoptotic pathways. He has identified novel therapeutic targets including CXCR4 and PDK1, leading to two biotech start-ups and multiple patents. His interdisciplinary CBMIT team integrates immunology, virology, medicinal chemistry, and computational modeling to develop innovative therapeutic strategies and biomarkers. He has a keen interest in immunomodulation, therapeutic interference with IFN pathways, and discovery of druggable checkpoints in innate immunity. With over 70 peer-reviewed publications, his scientific output has shaped current understanding of immune pathogenesis and opened new avenues for therapy in inflammatory and infectious diseases. His approach bridges fundamental research with practical applications in drug discovery and biotech development.

📚 Publications Top Notes:

  1. 🧬 HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells

  2. ⚰️ CD4+ T-cell death induced by infectious and noninfectious HIV-1: role of type 1 interferon–dependent, TRAIL/DR5-mediated apoptosis

  3. 🚻 Sex differences in plasmacytoid dendritic cell levels of IRF5 drive higher IFN-α production in women

  4. 🧪 HIV-1 immunopathogenesis: how good interferon turns bad

  5. 🔄 Regulation of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA-synthetase by CTLA-4-Fc in human CD4+ T cells

  6. 🧠 Differential expression of IFN-α and TRAIL/DR5 in lymphoid tissue of progressor vs. nonprogressor HIV-1-infected patients

  7. 🧟 HIV turns plasmacytoid dendritic cells into TRAIL-expressing killer pDC via TLR7-induced IFN-α

  8. 🧬 Regulation of TRAIL on primary CD4+ T cells by HIV-1: role of plasmacytoid dendritic cells

  9. 💉 TRAIL in HIV-1–infected patients and its production by antigen-presenting cells

  10. 🧫 Recruitment of STAT3 for production of IL-10 by colon carcinoma cells induced by macrophage-derived IL-6

🧾 Conclusion:

Dr. Jean-Philippe Herbeuval stands out as a highly qualified and deserving candidate for the Best Innovator Award. His rare combination of scientific excellence, translational innovation, entrepreneurial leadership, and mentorship places him in the top tier of biomedical innovators. His work not only bridges science and industry but also directly contributes to addressing global health challenges. Continued support and recognition of his efforts will likely catalyze further innovation in therapeutic immunology.

An Dai Tran | Immunology Cellular Interactions | Best Researcher Award

Posted on by sciencefather

Mr. An Dai Tran | Immunology Cellular Interactions | Best Researcher Award

Mr. An Dai Tran, Walailak University, Vietnam

Dr. An Dai Tran is a dedicated medical doctor and emerging public health researcher from Vietnam, currently pursuing a Master’s degree at Walailak University, Thailand. He works at the CDC Dong Thap, focusing on vaccination programs and infectious disease control, including dengue fever, COVID-19, and measles. With several years of hands-on experience in clinical trials and epidemiological research, Dr. Tran has made significant contributions to community health. His published work on vaccination adherence among minority groups in Vietnam has had real-world impact on public health campaigns. Additionally, he has co-developed innovative tools for behavioral science and contributed to machine learning applications in mental health. Collaborating with global institutions such as the University of Queensland and the Pasteur Institute, Dr. Tran’s work reflects a commitment to translational research, public health equity, and data-driven health interventions. His profile is marked by scientific rigor, international collaboration, and service to underserved populations.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. Interdisciplinary Research Excellence
    Dr. Tran’s research spans infectious diseases, vaccination behavior, and digital mental health—demonstrating versatility and innovation in addressing modern public health challenges.

  2. Practical and Policy-Relevant Impact
    His work on vaccination adherence in minority communities has real-world implications for national health policy and outreach programs, especially in underserved populations.

  3. Strong Clinical Trial Experience
    He has held critical roles in major vaccine trials (COVID-19 and hand-foot-mouth disease), showing competence in trial design, blinding, and coordination—essential for translational health research.

  4. Collaborative Global Network
    Dr. Tran has established collaborations with renowned institutions such as the University of Queensland and the Pasteur Institute, boosting the credibility and scalability of his research.

  5. Innovation in Mental Health Analytics
    His application of AI and machine learning to post-COVID mental health challenges shows forward-thinking research methodology with future potential.

  6. Published and Cited
    With publications in peer-reviewed journals like Jornal de Pediatria and Journal of Human, Earth, and Future, and a growing citation index, he is building a solid academic foundation.

🛠️ Areas for Improvement:

  1. Broader Indexing and Citations
    While promising, most of his current publications are in emerging or interdisciplinary journals. Publishing in higher-impact, SCI-indexed journals could enhance academic visibility.

  2. Editorial and Peer Review Roles
    Taking on editorial appointments or peer-review duties would strengthen his professional profile and leadership in research.

  3. Mentorship and Teaching Contribution
    Engaging in formal mentorship or academic teaching roles would reflect his potential as a knowledge disseminator and academic influencer.

  4. Expanded Public Health Policy Impact
    Future work that integrates direct contributions to policy development or national programs would further validate his applied research strengths.

🎓 Education:

Dr. An Dai Tran holds a medical degree and is currently completing a Master’s in Public Health at the School of Public Health, Walailak University, Thailand. He was awarded a full scholarship for his postgraduate studies in recognition of his academic excellence and commitment to public health. His education bridges clinical medicine with population-level health sciences, equipping him with multidisciplinary expertise to tackle emerging global health challenges. At Walailak University, Dr. Tran has deepened his knowledge in epidemiology, biostatistics, global health policy, and digital health technologies. His academic training is complemented by a strong foundation in research methodology and ethics, allowing him to conduct high-impact studies and clinical trials. His exposure to both theoretical and practical facets of public health, along with mentorship from international experts, positions him as a future leader in healthcare innovation, with special focus on vaccine-preventable diseases and mental health research in Southeast Asia.

💼 Professional Experience:

Dr. Tran brings valuable on-ground experience through his work at the CDC Dong Thap in Vietnam, where he has led and supported various national vaccination campaigns and infectious disease monitoring systems. He has been actively involved in both the operational and research aspects of public health interventions. His clinical trial roles include coordinating blinded and double-blinded studies on COVID-19 and hand-foot-mouth vaccines. Notably, he served as a research coordinator in large-scale, placebo-controlled trials with rigorous ethical and methodological frameworks. His consultancy record includes four projects in collaboration with governmental and academic institutions, such as the University of Queensland (E-Dengue Project) and the Pasteur Institute (Vietnam-based vaccine research). Dr. Tran’s experience spans public health research, disease surveillance, behavioral analysis, and machine learning for mental health prediction. His combined roles as physician, coordinator, and academic researcher highlight his versatility, responsibility, and drive for impactful health innovations that reach marginalized communities.

🧠 Research Focus:

Dr. Tran’s research lies at the intersection of infectious diseases, vaccination behavior, and digital mental health. His primary interest is understanding the behavioral and sociocultural factors affecting vaccine uptake, particularly among ethnic minority populations. His first-author publication on this topic has already contributed to improved regional strategies for vaccine delivery. Expanding into digital health, Dr. Tran has co-developed psychological assessment tools and applied machine learning to detect mental health issues in post-COVID patients. His work in computational psychiatry includes Reddit-based community sentiment analysis and comparative modeling for long COVID mental health prediction. By merging AI with public health, he aims to enhance early detection and intervention systems. His approach reflects a holistic vision—bridging clinical practice, community outreach, and technology—with a commitment to healthcare equity. Dr. Tran’s research is not only academically sound but also practically applicable, aligning with Sustainable Development Goals (SDGs) for health and well-being.

📚 Publications Top Notes:

  1. 🧬 Parental predictors of childhood vaccination adherence in border areas of Southern Vietnam – Jornal de Pediatria.

  2. 🏃‍♂️ Initial Construction of the Exercise Maintenance Motivation Scale: A Mixed Method Study – Journal of Human, Earth, and Future.

  3. 🤖 An Analysis of Machine Learning for Detecting Depression, Anxiety, and Stress of Recovered COVID-19 Patients – Journal of Human, Earth, and Future.

  4. 🧠 Exploring Mental Stress Expressions in Online Communities: A Subreddit Analysis – Journal of Human, Earth, and Future.

  5. 🧪 Mental health and long COVID status prediction among recovered COVID-19 patients: A comparison of machine learning methods – Journal of Human, Earth, and Future.

🧾 Conclusion:

Dr. An Dai Tran is a highly promising early-career researcher whose interdisciplinary work in public health is both scientifically rigorous and socially impactful. His blend of clinical trial expertise, digital health innovation, and public health behavior research makes him an ideal candidate for the Best Researcher Award. While there is room to grow in areas like journal prestige and academic leadership, his current trajectory, achievements, and commitment to health equity clearly demonstrate award-worthy excellence.